2.31

3.75% -0.09

After Hours: 2.31

Indaptus Therapeutics Inc (INDP)

Overview News Price History Financials Discussions Forecast

Indaptus Therapeutics Inc stock is currently priced at $2.31, with a 24-hour trading volume of 5,955. It has seen a -3.75% decreased in the last 24 hours and a -13.16% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $2.33 pivot point. If it approaches the $2.27 support level, significant changes may occur.

Previous Close:

$2.40

Open:

$2.39

24h Volume:

5,955

Market Cap:

$19.72M

Revenue:

Net Income/Loss:

$-15.42M

P/E Ratio:

-1.3125

EPS:

-1.76

Net Cash Flow:

$-13.41M

1W Performance:

+7.44%

1M Performance:

-13.16%

6M Performance:

+12.14%

1Y Performance:

+12.68%

1D Range:

$2.31

$2.41

52W Range:

$1.56

$4.08

Indaptus Therapeutics Inc Stock (INDP) Company Profile

Name

Indaptus Therapeutics Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

646 427 2727

Address

3 Columbus Circle, 15th Floor, New York

Employee

Twitter

Next Earnings Date

2024-05-03

Latest SEC Filings

INDP's Discussions on Twitter

Indaptus Therapeutics Inc Stock (INDP) Latest News

Indaptus Therapeutics (NASDAQ:INDP) Shares Up 1.5% - Defense World

Defense World

Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire Inc.

Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update - Investing.com India

Investing.com India

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

GlobeNewswire Inc.

Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Invest In Growth? - Yahoo Finance

Yahoo Finance

Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting

GlobeNewswire Inc.

Indaptus Therapeutics Inc Stock (INDP) Financials Data

Indaptus Therapeutics Inc (INDP) Net Income 2024

INDP net income (TTM) was -$15.42 million for the quarter ending December 31, 2023, a -7.68% decrease year-over-year.

Indaptus Therapeutics Inc (INDP) Cash Flow 2024

INDP recorded a free cash flow (TTM) of -$13.41 million for the quarter ending December 31, 2023, a -2.50% decrease year-over-year.

Indaptus Therapeutics Inc (INDP) Earnings per Share 2024

INDP earnings per share (TTM) was -$1.84 for the quarter ending December 31, 2023, a -6.36% decline year-over-year.

Indaptus Therapeutics Inc Stock (INDP) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Anderson Glen R.	10% Owner	Aug 11 '23	Buy	2.12	35,064	74,336	1,166,466
Anderson Glen R.	10% Owner	Aug 10 '23	Buy	1.94	44,354	86,047	1,131,402

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is based in New York, New York.